Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01952574 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 483
- Enrollment target
NCT01952574: Completed Phase 2 study, sponsored by Amgen.
NCT01952574 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 483 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (263% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01952574, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 483 participants
- Enrollment target
Study Summary
A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
Primary Outcome
A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura. The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine days during the 4-week baseline phase.
Interventions
- DRUG Placebo
- DRUG Erenumab
- DRUG Erenumab PFS
- DRUG Erenumab AI/Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2013-08-06 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
What the finished NCT01952574 record still lists
NCT01952574 is an interventional study that assigns participants to a tested intervention. The registered 483 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (263% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01952574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01952574 about?
NCT01952574 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention". A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
What is the current status of trial NCT01952574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 483 participants. The study started on 2013-08-06. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT01952574?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG), Erenumab PFS (DRUG), Erenumab AI/Pen (DRUG).
Who is sponsoring clinical trial NCT01952574?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01952574's enrollment target sits among peer trials
483 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI